HFrEF Agent Pearls

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/45

encourage image

There's no tags or description

Looks like no tags are added yet.

Last updated 6:21 PM on 10/9/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai
Chat

No analytics yet

Send a link to your students to track their progress

46 Terms

1
New cards

The transition from which drug to which drug requires a wash-out period? How long is that wash-out period?

ACEi to ARNi

  • ARNi should only be taken after waiting 36 hours following stopping ACEi — due to angioedema risk

  • This does not apply to ARBs; if switching from ARB to ARNi, can schedule ARNi as next dose


2
New cards

Criteria to stop/hold/dose reduce ARNi/ACEi/ARB

  • SCr increase >30% within 2-4 weeks of initiation/dose change

  • SCr increase by ≥0.3 mg/dL within 48 hours after initiation/dose change


3
New cards

Which HFrEF drug falsely elevates BNP and makes it an unreliable marker of disease progression?

ARNis

4
New cards

Selectivity of metoprolol succinate?

Beta-1 selective

5
New cards

Selectivity of bisoprolol?

Beta-1 selective

6
New cards

Selectivity of carvedilol?

Beta-1 and -2 nonselective, and alpha antagonist as well

7
New cards

Which beta-blocker used in HFrEF has the most appreciable blood pressure lowering?

Carvedilol

8
New cards

Which HFrEF GDMT agent must we wait before initiating? What are we waiting for, and why?

Beta-blockers; wait until patient is no longer acutely symptomatic and is euvolemic

  • Because beta-blockers can acutely worsen symptoms


9
New cards

How often should beta-blockers be up-titrated when gradually increasing to target / maximally tolerated dose?

Wait AT LEAST 2 weeks after initiation / previous dose increase

10
New cards

Patient status requirement for beta-blocker up-titration?

Stable and euvolemic

11
New cards

What two renal criteria must a HFrEF patient meet to be able to receive an MRA?

Renal criteria:

  • eGFR >30 mL/min/1.73m2

  • K+ <5 mEq/L


12
New cards

What baseline SCr values are contraindications to MRA use for HFrEF patients?

Men: SCr >2.5 mg/dL

Women: SCr >2.0 mg/dL

13
New cards

When should you discontinue an MRA in a HFrEF patient?

If K+ goes >5.5 mEq/L during MRA treatment

14
New cards

Which MRA causes gynecomastia?

Spironolactone

15
New cards

Which MRA should you switch to in order to help avoid gynecomastia?

Eplerenone

16
New cards

MRA monitoring schedule?

On day 3, on day 7, then monthly for 3 months, then every 3 months

17
New cards

What is the eGFR requirement for initiation of dapagliflozin?

Baseline eGFR ≥25 mL/min/1.73m2

18
New cards

What is the eGFR requirement for initiation of sotagliflozin?

Baseline eGFR ≥25 mL/min/1.73m2

19
New cards

What is the eGFR requirement for initiation of empagliflozin?

Baseline eGFR ≥20 mL/min/1.73m2

20
New cards

What initial effect is usually seen upon initiation of an SGLT2 inhibitor?

Slight, transient worsening of renal function; NOT a reason to d/c

21
New cards

Which HFrEF drug has the “ceiling dose” consideration?

Loop diuretics — beyond a certain dose, they provide no more additional benefit and only increase the ADR risk

  • If still not achieving diuresis and euvolemia at ceiling dose, start dosing BID


22
New cards

HFrEF loop diuretic equivalent dosing

Bumetanide 1 mg = torsemide 20 mg = furosemide 40 mg

23
New cards

Which of the HFrEF GDMT meds is not titrated to a guideline-directed specific target dose?

Loop diuretics

  • Instead, use the lowest efficacious dose for the patient’s volume overload (if they have volume overload)


24
New cards

Which HFrEF drug should you consider taking an extra dose of if notable weight gain is observed?

Loop diuretic

25
New cards

What parameter should be monitored for loop diuretic efficacy in HFrEF?

Weight

  • Increase of 1 lb/day for several days, or increase of 3-5 lb (~2 kg) in a week should prompt evaluation for a loop diuretic dose increase


26
New cards

Which HFrEF drug is associated with quick and acute worsening of symptoms if missed doses?

Loop diuretics

27
New cards

Which HFrEF drug has challenging dosing due to being TID?

Hydralazine/isosorbide dinitrate

28
New cards

Which HFrEF drug is most associated with drug-induced lupus?

Hydralazine/isosorbide dinitrate (specifically the hydralazine component)

29
New cards

Ivabradine use criteria?

  • EF ≤35%, NYHA II-III (not studied in class IV)

  • Normal sinus rhythm (no afib) with resting HR ≥70 bpm

  • Already on max-tolerated beta-blocker dose


30
New cards

How should ivabradine be administered?

With food

31
New cards

Which HFrEF drug is contraindicated with atrial fibrillation?

Ivabradine — must be in sinus rhythm to initiate

32
New cards

What resting heart rate is contraindicated with ivabradine?

<60 bpm (and remember to initiate ivabradine, resting heart rate must be ≥70 bpm — bc ivabradine slows down the heart rate!)

33
New cards

What three medical conditions are ivabradine contraindicated with?

  • HFpEF

  • Acute decompensated heart failure

  • Atrial fibrillation


34
New cards

Ivabradine initiation should be considered in relation to what GDMT med?

Beta-blockers; must be on maximum tolerated beta-blocker therapy (and done with titration stage) before ivabradine is used

35
New cards

Which HFrEF drug is associated with blurred vision (phosphenes)?

Ivabradine

36
New cards

Which HFrEF drug is associated with bradycardia?

Ivabradine

37
New cards

Which HFrEF drug is associated with atrial fibrillation?

Ivabradine

38
New cards

Which HFrEF drug is associated with heart block?

Ivabradine

39
New cards

Vericiguat use criteria

“May consider” if all of the following:

  • High-risk HFrEF

    • “High-risk HFrEF” = elevated BNP (>300, or NT-pro-BNP >1000) at baseline

  • Worsening HF

    • “Worsening HF” = HF hospitalization within 6 months OR need for outpatient IV diuretics

  • On optimized GDMT


40
New cards

Which HFrEF drug is most associated with anemia (Hb, Hct)?

Vericiguat

41
New cards

Which HFrEF drug has an interaction with PDE5 inhibitors (e.g. sildenafil, tadalafil) and should not be administered with them?

Vericiguat — due to hypotension risk

42
New cards

Digoxin use criteria

May consider adding to optimized GDMT if meets one of the two criteria:

  • Symptomatic

  • Patient unable to tolerate other GDMT


43
New cards

Which HFrEF drug is associated wiht halos/photophobia?

Digoxin

44
New cards

Which HFrEF drug is noted for a narrow therapeutic window?

Digoxin

45
New cards

What increases risk of digoxin toxicity?

Hypokalemia or hypomagnesemia

46
New cards

Digoxin target levels for HFrEF?

0.5-1 mg/dL

  • For HFrEF, definitely don’t want ≥1 mg/dL